Transforming early disease detection with validated autonomous AI.
We are thrilled to announce that Eyenuk has been named to TIME's list of the World's Top HealthTech Companies for 2026.
Presented by TIME in partnership with global data research firm Statista, this annual recognition identifies the most innovative and impactful digital health companies delivering technologies that make healthcare more effective, efficient, and globally accessible.
Out of thousands of health technology companies evaluated across the globe, Eyenuk was selected among the top 500 most innovative and impactful companies, earning a distinct placement as one of the top 100 industry leaders in the AI & Data Analytics category.
Comprehensive evaluation across the globe
TIME and Statista conducted a comprehensive evaluation to determine the world's top HealthTech organizations. Companies were assessed using a weighted scoring model across financial performance (50%), reputation analysis (30%), and online engagement (20%).
Eyenuk's recognition reflects our commitment to making healthcare more accessible globally and validates our position in the global AI diagnostic landscape.
Advancing systemic health through retinal AI
Eyenuk's selection for the AI & Data Analytics category is a direct reflection of our foundational mission: to prevent vision- and life-threatening disease and advance system health through retinal AI.
"Traditional eye screening models cannot keep pace with rising disease prevalence and global workforce shortages. This recognition from TIME reflects the progress we have made showing that autonomous AI can close the gap and deliver screening at the scale population health requires."
- Gaurav Agarwal, CEO of Eyenuk
Looking ahead
At Eyenuk, our ultimate motivation is the patient. We firmly believe that healthcare access is for everyone, and that early detection enables proactive care.
As digital health technology continues to transform patient outcomes worldwide, Eyenuk remains dedicated to pushing the boundaries of AI-driven disease detection. We extend our gratitude to our clinical partners, research collaborators, investors, and team members who make this progress possible every day.